Genmab — November 2018
-
Men der var jo ikke tale om en ny opskrift. Det er der med dara sc + rhuph20. Supplements with CMC formulation changes and supplements with pharmacology/toxicology data will be excluded. https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/OCE/ucm612927.htm
-
Nu kender de jo begge stoffer ganske godt. Men det er da muligt du har ret. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM217043.pdf
-
Daratumumab in Combination with Vincristine or Nelarabine As Effective Salvage Therapy for Patients with Acute Lymphoblastic Leukemia at High Risk of Relapse http://www.bloodjournal.org/content/132/Suppl_1/5206
-
En anbefalelsesværdig video for alle aktieinvestorer.
-
Hvor er I alle henne? Savner jer
-
Gen følger naturligvis markedet. Men i sidste uge så (tror jeg) det klassiske, at TÁ kan bruges og at TÁ regelmæssigt ligger op til fundamentale fejlbeslutninger. Investorerne er ved at indrette sig på, at de ikke kan handle imod facts længere. Trenden for Genmab er i vending, ikke at det sker uden sværdslag, men isoleret (fra markedstendensen) er Gen på vej opad til det den fortjener
-
God morgen.
-
2 more articles in Bloodjournal http://www.bloodjournal.org/content/132/Suppl_1/2255 http://www.bloodjournal.org/content/132/Suppl_1/1663
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind